Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Solid Tumor 1Neoplasms 1Lung Neoplasms 1Carcinoma 1

Interventions

senaparib 7pembrolizumab 7Irinotecan 6Paclitaxel 5Docetaxel 5Cisplatin 5Capecitabine 5Nivolumab 4Fluorouracil 4Bevacizumab 4Rifampin 3Midazolam 3Leucovorin 3Itraconazole 3Injections 3pertuzumab 2ontuxizumab 2navoximod 2atezolizumab 2Gemcitabine 2vofatamab 1tremelimumab 1trastuzumab duocarmazine 1talazoparib 1sotorasib 1sintilimab 1saracatinib 1rucaparib 1ridaforolimus 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumor × ensartinib × Clear all
NCT02959619 2023-08-21

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
48 enrolled
Other solid neoplasmThoracic

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡